$LOGC

ContextLogic Holdings Inc. (LOGC): Results of Operations and Financial Condition

ContextLogic Holdings Inc. (LOGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 logc-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 ContextLogic Holdings Inc. Reports Second-Quarter 2026 Financial Results OAKLAND, Calif., August 13, 2026 ( GLOBE NEWSWIRE ) -- ContextLogic Holdings Inc. (OTCQB: LOGC) ("ContextLogic," the "Company," "we" or "our") today rep

Original reporting
Published Aug 13, 2026, 8:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$LOGC
Bearish
medium confidence
Mentioned
$LOGC
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LOGCBearishMed
01

Why it matters

Q2 revenue was essentially flat year over year, but gross profit fell, GAAP net loss widened, and free cash flow turned sharply negative, with management attributing key drivers to parent-level costs and US Salt acquisition transaction expenses.

02

Market read

This is a primary earnings-style disclosure with concrete P&L and cash-flow numbers, plus acquisition-related cost explanations that can drive immediate repricing.

03

What to watch

The release highlights volume decline from planned maintenance and trucking constraints, so traders should separate demand/operational issues from one-time acquisition accounting and transaction expenses.

Relevance 7/10Novelty 8/10Timing: after-hours filing of Q2 2026 financial results (8-K)

Background

ContextLogic completed the US Salt acquisition on Feb. 26, 2026, and the filing presents Predecessor versus Successor periods plus Combined non-GAAP results.

Company-level read

Ticker impact

$LOGCBearishMedium confidence
Context

ContextLogic reported Q2 2026 results, including a $6.3M net loss and $10.8M adjusted EBITDA, plus a sharp free-cash-flow decline tied to US Salt acquisition costs.

Expected impact

Near-term volatility risk is elevated as traders reprice margin and cash-flow trajectory post-acquisition; follow-through depends on whether investors focus on adjusted EBITDA versus GAAP losses.

Evidence & confidence

The article discloses specific quarter and six-month figures (revenue flat, gross profit down, net loss wider, free cash flow deeply negative) and attributes declines to parent-level costs and US Salt acquisition transaction expenses, which can drive sentiment and valuation debates.

Market effects

For small-cap business-ownership platforms, the mix of acquisition-related costs versus operating performance can influence sector risk appetite.

Limited, primarily affects US microcap/OTC sentiment rather than broad regional fundamentals.

Low, as the disclosure is company-specific and not tied to global macro or cross-border regulatory actions.

Counterpoint

Investors may discount GAAP net loss and focus on adjusted EBITDA, which is still positive at $10.8M, arguing the cash-flow deterioration is largely acquisition-driven and potentially temporary.

Key entities

  • ContextLogic Holdings Inc.

    OTCQB-listed company reporting Q2 2026 results on Form 8-K, including GAAP net loss, adjusted EBITDA, and free cash flow.

  • US Salt Parent Holdings, LLC

    Acquisition completed Feb. 26, 2026; transaction expenses and acquisition accounting affect reported results.

Related articles

$LOGCMedAI 8/10

Latham Represents Blackstone Credit & Insurance in Financing for ContextLogic’s Acquisition of gChem for US$850 Million

ContextLogic Holdings (OTCQB: LOGC) said it will acquire gChem, the holding company of Gaylord Chemical and subsidiaries, from funds managed by EagleTree Capital and co-investors. The deal values gChem at an enterprise value of US$850 million. Financing will come from Blackstone Credit & Insurance, including a US$250 million term loan and US$25 million revolver, per the company.

$LOGCMed

ContextLogic Holdings Inc. (LOGC): Results of Operations and Financial Condition

ContextLogic Holdings Inc. (LOGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-2.1 2 logc-ex2_1.htm EX-2.1 EX-2.1 Exhibit 2.1 STOCK PURCHASE AGREEMENT BY AND AMONG EAGLETREE-GAYLORD MANAGEMENT INVESTMENT, L.P., EAGLETREE-GAYLORD HOLDINGS CORP. GCH BUYER, Inc. and SOLELY FOR THE PURPOSES OF ARTICLE VIII and the defined terms used therein, CONTEXTLOGIC HOL

$LOGCLow

ContextLogic appoints Cantaloupe alum to dual CFO, COO seat

ContextLogic said Scott Stewart, an Intercontinental Exchange alumnus, will serve as both CFO and chief operating officer effective immediately, succeeding interim finance chief Chad Chevalier, according to company filings. Stewart previously was CFO of Cantaloupe. The move follows leadership changes after ContextLogic’s 2024 $161 million asset sale and its US Salt acquisition valued at $907.5 million. In Q1 2026, it reported non-GAAP net income of $17 million.

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Results of Operations and Financial Condition

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 3 d48818dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of August 13, 2026, by and among MapLight Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each of the purcha

$RNAMed

Atrium Therapeutics, Inc. (RNA): Results of Operations and Financial Condition

Atrium Therapeutics, Inc. (RNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d149126dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results — IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome — — Achieved second milestone payment under global cardiovascular col

$CLDIMed

Calidi Biotherapeutics, Inc. (CLDI): Results of Operations and Financial Condition

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a firs

ContextLogic Holdings Inc. (LOGC): Results of Operations and Financial Condition — alphai